{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:14:24Z","timestamp":1771668864257,"version":"3.50.1"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2019-0025_s_999_w2aab3b7b7b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical practices and testing strategies in patients with ovarian cancer differ worldwide. We therefor wanted to give an overview over the current data to advise best clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0025_s_998_w2aab3b7b7b1b6b1aab1c14b2Aa\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      A systematic review of the literature was performed with the aim to define which ovarian cancer patients to refer for genetic counseling and how to perform genetic testing. We also discuss the timing of genetic testing and clinical relevance of the\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutation status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0025_s_997_w2aab3b7b7b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The germline mutation rate in patients with ovarian cancer is high, independent of family history, age at diagnosis and histology.\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutation carriers with ovarian cancer have improved survival rates. In recurrent ovarian cancer treatment by poly ADP ribose polymerase (PARP) inhibitors improves the disease-free survival in patients with\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutations or homologous recombination deficiency with hazard ratios up to 0.23. But also patients with\n                      <jats:italic>BRCA<\/jats:italic>\n                      wild type show a benefit. The recently published SOLO-1 trial demonstrated a significant benefit for patients with germline\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutations in the first line setting. By tumor testing about 7% additional\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutations can be found but the somatic testing and interpretation of the results remains a challenge. Despite the clinical impact, analysis of our own data and also international publications show insufficient referral rates for genetic counseling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0025_s_996_w2aab3b7b7b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genetic testing in ovarian cancer has a prognostic and predictive value. Referral rates must be improved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2019-0025","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T05:02:56Z","timestamp":1569992576000},"source":"Crossref","is-referenced-by-count":5,"title":["Genetic testing in ovarian cancer \u2013 clinical impact and current practices"],"prefix":"10.1515","volume":"41","author":[{"given":"Laura","family":"Knabben","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology , University Hospital of Berne and University of Berne , Effingerstrasse 102 , 3010 Berne , Switzerland , Phone: +41 31 632 10 10, Fax: +41 31 632 12 05"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Imboden","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology , University Hospital of Berne and University of Berne , 3010 Berne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel D.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology , University Hospital of Berne and University of Berne , 3010 Berne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"2025121207150566730_j_hmbci-2019-0025_ref_001_w2aab3b7b7b1b6b1ab2b1b1Aa","unstructured":"Andt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni C, et al. Cancer in Switzerland 2011\u20132015 (Schweizerischer Krebsbericht 2015,) Swiss Federal Statistical Office (Bundesamt f\u00fcr Statistik), Neuch\u00e2tel, 2016."},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_002_w2aab3b7b7b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed ovarian carcinoma: ESMO Clinical Practice Guidelines for Diagnostics, Treatment and Follow-Up. Ann Oncol. 2013;24(6):vi24\u2013vi32.","DOI":"10.1093\/annonc\/mdt333"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_003_w2aab3b7b7b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality. J Am Med Assoc. 2011;305:2295.","DOI":"10.1001\/jama.2011.766"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_004_w2aab3b7b7b1b6b1ab2b1b4Aa","unstructured":"National Academies of Sciences, Engineering and Medecine. Ovarian Cancers: Evolving paradigms in research and care. 2016."},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_005_w2aab3b7b7b1b6b1ab2b1b5Aa","unstructured":"Survival Rates for Ovarian Cancer, by Stage. https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed April 6, 2019."},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_006_w2aab3b7b7b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:18032\u20137.","DOI":"10.1073\/pnas.1115052108"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_007_w2aab3b7b7b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc. 2017;317:2402\u201316.","DOI":"10.1001\/jama.2017.7112"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_008_w2aab3b7b7b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Soegaard M, Kjaer SK, Cox M, Wozniak E, H\u00f8gdall E, H\u00f8gdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14:3761\u20137.","DOI":"10.1158\/1078-0432.CCR-07-4806"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_009_w2aab3b7b7b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. J Am Med Assoc Oncol. 2016;2:482\u201390.","DOI":"10.1001\/jamaoncol.2015.5495"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_010_w2aab3b7b7b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363.","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_011_w2aab3b7b7b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Finch AP, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547\u201353.","DOI":"10.1200\/JCO.2013.53.2820"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_012_w2aab3b7b7b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Consortium of Investigators of Modifiers of BRCA1\/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134\u201347.","DOI":"10.1016\/j.yobg.2012.05.049"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_013_w2aab3b7b7b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217:334.e1\u2013e9.","DOI":"10.1016\/j.ajog.2017.05.036"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_014_w2aab3b7b7b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. J Am Med Assoc. 2012;307:382\u201390.","DOI":"10.1001\/jama.2012.20"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_015_w2aab3b7b7b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764\u201375.","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_016_w2aab3b7b7b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, et al. BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol. 2016;140:443\u20139.","DOI":"10.1016\/j.ygyno.2015.12.027"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_017_w2aab3b7b7b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","DOI":"10.1056\/NEJMoa1105535"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_018_w2aab3b7b7b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving Olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579\u201389.","DOI":"10.1016\/S1470-2045(16)30376-X"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_019_w2aab3b7b7b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852\u201361.","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_020_w2aab3b7b7b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_021_w2aab3b7b7b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_022_w2aab3b7b7b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","DOI":"10.1056\/NEJMoa1611310"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_023_w2aab3b7b7b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","DOI":"10.1056\/NEJMoa1104390"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_024_w2aab3b7b7b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","DOI":"10.1056\/NEJMoa1103799"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_025_w2aab3b7b7b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","DOI":"10.1056\/NEJMoa1810858"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_026_w2aab3b7b7b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15\u201328.","DOI":"10.1016\/S1470-2045(18)30786-1"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_027_w2aab3b7b7b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Pili\u00e9 PG, Gay CM, Byers LA, O\u2019Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759\u201371.","DOI":"10.1158\/1078-0432.CCR-18-0968"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_028_w2aab3b7b7b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570\u20136.","DOI":"10.1200\/JCO.2009.27.2997"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_029_w2aab3b7b7b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","DOI":"10.1038\/nature10166"},{"key":"2025121207150566730_j_hmbci-2019-0025_ref_030_w2aab3b7b7b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145:130\u20136.","DOI":"10.1016\/j.ygyno.2017.01.030"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/hmbci\/41\/3\/article-20190025.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0025\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0025\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:03:41Z","timestamp":1765526621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0025\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,17]]},"published-print":{"date-parts":[[2020,9,23]]}},"alternative-id":["10.1515\/hmbci-2019-0025"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0025","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"article-number":"20190025"}}